9:50 PM
 | 
Nov 02, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Effector begins Phase II trial of eFT508 plus Bavencio

Effector Therapeutics Inc. (San Diego, Calif.) began a Phase II trial of eFT508 with or without PD-L1 inhibitor Bavencio avelumab (MSB0010718C, PF-06834635) to treat microsatellite stable colorectal cancer (CRC). Part one of the open-label, U.S. trial will evaluate escalating doses of twice-daily oral eFT508 plus 10 mg/kg IV Bavencio every...

Read the full 226 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >